EUVIMEDEUVIMED entdecken
Crossref

Empagliflozin Ameliorates Angiotensin II‐Induced Left Ventricular Diastolic Dysfunction by Suppressing EndoMT via PI3K/AKT/eNOS Signaling

Dong-Li Shen iD, Zi-Mu Wang, Yan-Yan Wang, Zhong-Lei Xie, Shuai Yuan, Bao-Zhen Qi, Shun Yao, Xiao-Tong Cui, Yu Song, Xue-Ting Han, Jun-Bo Ge iD, Jing-Min Zhou

The Journal of Gene Medicine · 2026-05 · 28 (5)

DOI: 10.1002/jgm.70096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Gene Medicine, online erschienen am 30.04.2026. Verfasst von Dong-Li Shen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for …. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Angiotensin II, Signal Transduction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The SGLT2 inhibitor empagliflozin (EMPA) has been found to reduce the combined risk of cardiovascular death or hospitalization for heart failure in patients with or without reduced left ventricular ejection fraction, irrespective of diabetes status. The underlying mechanisms remain to be elucidated. Endothelial‐to‐mesenchymal transition (EndoMT) has been reported to play a pivotal role in the microvascular rarefaction. This study aimed to evaluate the effect of EMPA on angiotensin II (Ang II)‐induced left ventricular dysfunction and to explore the underlying mechanism.

Methods

In vivo, C57BL/6J mice were infused with saline or Ang II (1.5 mg/kg/day) and subsequently treated with or without EMPA (10 mg/kg) for 2 weeks. mRNA sequencing and gene set enrichment analysis (GSEA) indicated that the PI3K/AKT/eNOS signalling pathway may mediate the protective effects of empagliflozin in heart failure with preserved ejection fraction (HFpEF). Finally, in vitro, PI‐103 was used to treat cells, and immunofluorescence, western blotting, qPCR, and other methods were used to verify whether empagliflozin exerts its effects through the PI3K/AKT/eNOS pathway.

Results

In vivo, the mice treated with Ang II exhibited left ventricular dysfunction, increased microvascular rarefaction, and EndoMT, all of which were attenuated by EMPA treatment. In vitro, primary cardiac microvascular endothelial cells (CMECs) exposed to Ang II showed increased EndoMT, which was significantly inhibited by EMPA. EMPA also reversed the downregulation of PI3K/AKT/eNOS signalling and nitric oxide (NO) levels. PI‐103 abrogated the anti‐EndoMT effects of EMPA in CMECs.

Conclusions

Our study suggested that EMPA can protect against Ang II‐induced left ventricular dysfunction and microvascular rarefaction by suppressing EndoMT via PI3K/AKT/eNOS signalling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesAngiotensin IISignal TransductionVentricular Dysfunction, LeftNitric Oxide Synthase Type IIIEndothelial-Mesenchymal TransitionAnimalsProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesMiceMaleMice, Inbred C57BLDisease Models, AnimalSodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

empagliflozinendothelial‐to‐mesenchymal transitionleft ventricular diastolic dysfunctionmicrovascular rarefaction

Substanzen

Benzhydryl CompoundsempagliflozinGlucosidesAngiotensin IIProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesNitric Oxide Synthase Type IIISodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.
  • Department of Cardiology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
  • Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
  • Department of Cardiology, Shanghai Geriatrics Medical Center (Minhang Campus, Zhongshan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Dong-Li Shen, Jun-Bo Ge

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Shen, D. L., Wang, Z. M., Wang, Y. Y., Xie, Z. L., Yuan, S., Qi, B. Z., Yao, S., Cui, X. T., Song, Y., Han, X. T., Ge, J. B., & Zhou, J. M. (2026). Empagliflozin Ameliorates Angiotensin II‐Induced Left Ventricular Diastolic Dysfunction by Suppressing EndoMT via PI3K/AKT/eNOS Signaling. The Journal of Gene Medicine, 28(5). https://doi.org/10.1002/jgm.70096

Vancouver

Shen DL, Wang ZM, Wang YY, Xie ZL, Yuan S, Qi BZ, et al. Empagliflozin Ameliorates Angiotensin II‐Induced Left Ventricular Diastolic Dysfunction by Suppressing EndoMT via PI3K/AKT/eNOS Signaling. The Journal of Gene Medicine. 2026;28(5). doi:10.1002/jgm.70096

BibTeX
@article{Shen2026,
  author = {Shen, Dong-Li and Wang, Zi-Mu and Wang, Yan-Yan and Xie, Zhong-Lei and Yuan, Shuai and Qi, Bao-Zhen and Yao, Shun and Cui, Xiao-Tong and Song, Yu and Han, Xue-Ting and Ge, Jun-Bo and Zhou, Jing-Min},
  title = {Empagliflozin Ameliorates Angiotensin II‐Induced Left Ventricular Diastolic Dysfunction by Suppressing EndoMT via PI3K/AKT/eNOS Signaling},
  journal = {The Journal of Gene Medicine},
  year = {2026},
  volume = {28},
  number = {5},
  doi = {10.1002/jgm.70096}
}
Kostenlos starten →